Xijian Wang

Xijian Wang

Auto-generated profile, based on publicly available information

Xijian Wang

Department of Nephrology, Affiliated Hospital of Nantong University & Medical School of Nantong University, Nantong, 226001, PR China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2024 in Phytomedicine
Verified
Journal Article
Closed access
TXTianya Xiang
Tianya Xiang
XWXijian Wang
Xijian Wang
SHShujiao Huang
Shujiao Huang
KZKexin Zhou
Kexin Zhou
SFShengnan Fei
Shengnan Fei
XHXinzhong Huang
Xinzhong Huang

1 October 2025 in Bioactive Materials
Verified
Journal Article
Open access
LZLingling Zhang
Lingling Zhang
HGHaifeng Gong
Haifeng Gong
XGXuelian Gong
Xuelian Gong
BZBing Zhou
Bing Zhou
XWXijian Wang
Xijian Wang
XHXinzhong Huang
Xinzhong Huang
Chronic nephritis management remains challenging due to the compromised therapeutic efficacy and severe systemic complications of conventional glucocorticoid therapy. Here, we developed a bioinspired platelet-mediated delivery system (LN-DEX@PLT) that leverages platelet tropism toward injured glomeruli for precision drug delivery. This system integrates lipid nanoemulsion encapsulation with platelet-mediated hitchhiking delivery to achieve three key functionalities: (1) enhanced renal targeting demonstrated by 2.2-fold higher glomerular accumulation compared to free dexamethasone via In vivo imaging, (2) effective mitigation of glucocorticoid-induced metabolic toxicity evidenced by reduced fasting plasma glucose (5.2 ± 0.3 vs 8.3 ± 0.7 mmol/L in free DEX), suppression of hepatic gluconeogenic enzymes (PEPCK expression decreased by 43 %, G-6 Pase by 51 %, both p < 0.001), and suppressed body weight (-23.1 % versus free DEX group), and (3) dual-pathway therapeutic effects through IL-6/TNF-α suppression and p53-p21Cip1-mediated senescence delay. In Adriamycin-based chronic nephritis models, LN-DEX@PLT demonstrated superior renal protection with 81 % reduction in proteinuria (vs 33 % for free DEX). In LPS-induced and Adriamycin-based chronic nephritis models, LN-DEX@PLT demonstrated suppression of renal inflammation markers (IL-6 expression decreased to 68 %, TNF-α to 51 %) and macrophage infiltration (F4/80+ cells decreased 5.3-fold). This platelet-biohybrid system provides a clinically translatable paradigm for precision glucocorticoid therapy with reduced dosing frequency.